LOS ANGELES, Jan. 11, 2022 /PRNewswire/ -- ACELYRIN,
INC., a biopharma company focused on providing patients
life-changing new treatment options by identifying, acquiring, and
accelerating development and commercialization of promising drug
candidates, today announced the appointment of Melanie Gloria, BSN, as the company's chief
operating officer (COO). In this role, Ms. Gloria will oversee
business operations across the company.
A former oncology nurse, Ms. Gloria has two decades' experience
in the biotechnology industry having led a variety of research and
development (R&D) functions. She is an experienced people
leader who has managed large, diverse teams that achieved global
approvals for blockbuster and life-saving therapies at Abbott
(NYSE:ABT), AbbVie (NYSE: ABBV), and Horizon Therapeutics (NASDAQ:
HZNP). Before joining ACELYRIN, she was senior vice president of
development operations at Horizon.
"On behalf of the entire ACELYRIN leadership team, I am
delighted to welcome Melanie as our chief operating officer. She
joins us with a strong operational background and has led a variety
of R&D functions in multiple therapeutic areas," said
Shao-Lee Lin, M.D., Ph.D.,
co-founder and chief executive officer of ACELYRIN. "Her business
operations, healthcare, and leadership experience will benefit
ACELYRIN and our patients as we pursue our vision of bringing
life-changing therapies to those with serious diseases."
"I am thrilled to join ACELYRIN and this team of passionate
colleagues as we work together to change patients' lives with
innovative drug therapies," said Ms. Gloria. "I look forward to
working with Shao-Lee, our board, and leadership team to build our
organization and drive growth for our company and our investors. In
addition to business strategy and operations and R&D, I'm
passionate about mentoring and supporting others to achieve their
highest aspirations. The culture of 'Courageous Caring' at ACELYRIN
offers the ideal environment for this style of leadership."
Ms. Gloria's leadership experience in business operations and
clinical development spans multiple therapeutic areas, including
cardiovascular, immunology, inflammation, ophthalmology, oncology,
virology, and women's health. Throughout her career at Abbott,
AbbVie, and Horizon, she has enabled global approvals of therapies
including HUMIRA®, Viekera Pak®, Mavyret®, Skyrizi®, Rinvoq®,
TEPEZZA®, and ORILISSA®.
Ms. Gloria was named one of PharmaVOICE's 100 Most Inspiring
People, received the Crain's Notable Women in Health Care award,
and is a Healthcare Businesswomen's Association Luminary award
recipient. She serves on the board of directors for Lake County
Haven, an organization that empowers homeless women and their
children to achieve permanent, independent living. She received a
bachelor of science degree in nursing from the University of Illinois, Chicago.
ACELYRIN, INC. is a biopharma company
focused on providing patients life-changing new treatment options
by identifying, acquiring, and accelerating development and
commercialization of promising drug candidates and leveraging its
expertise to rapidly advance these medicines to patients. For more
information, please visit www.acelyrin.com.
View original content to download